Association Between Blood Pressure Control and Coronavirus Disease 2019 Outcomes in 45 418 Symptomatic Patients With Hypertension: An Observational Cohort Study. Issue 3 (16th December 2020)

• Record Type: Journal Article
• Authors: Sheppard, James P.; Nicholson, Brian D.; Lee, Joseph; McGagh, Dylan; Sherlock, Julian; Koshiaris, Constantinos; Oke, Jason; Jones, Nicholas R.; Hinton, William; Armitage, Laura; Van Hecke, Oliver; Lay-Flurrie, Sarah; Bankhead, Clare R.; Liyanage, Harshana; Williams, John; Ferreira, Filipa; Feher, Michael D.; Ashworth, Andrew J.; Joy, Mark P.; de Lusignan, Simon; Hobbs, F.D. Richard
• Is Part Of: Hypertension. Volume 77:Issue 3(2021)
• Page Start: 846
• Page End: 855
• Publication Date: 2020-12-16
• Subjects: blood pressure -- COVID-19 -- electronic health records -- mortality -- pandemic; Hypertension -- Periodicals; Hypertension -- Treatment -- Periodicals; 616.132005
• DOI: 10.1161/HYPERTENSIONAHA.120.16472
• Languages: English
• ISSNs: 0194-911X

Abstract

Abstract : Supplemental Digital Content is available in the text. Abstract : Hypertension has been identified as a risk factor for coronavirus disease 2019 (COVID-19) and associated adverse outcomes. This study examined the association between preinfection blood pressure (BP) control and COVID-19 outcomes using data from 460 general practices in England. Eligible patients were adults with hypertension who were tested or diagnosed with COVID-19. BP control was defined by the most recent BP reading within 24 months of the index date (January 1, 2020). BP was defined as controlled (<130/80 mm Hg), raised (130/80–139/89 mm Hg), stage 1 uncontrolled (140/90–159/99 mm Hg), or stage 2 uncontrolled (≥160/100 mm Hg). The primary outcome was death within 28 days of COVID-19 diagnosis. Secondary outcomes were COVID-19 diagnosis and COVID-19–related hospital admission. Multivariable logistic regression was used to examine the association between BP control and outcomes. Of the 45 418 patients (mean age, 67 years; 44.7% male) included, 11 950 (26.3%) had controlled BP. These patients were older, had more comorbidities, and had been diagnosed with hypertension for longer. A total of 4277 patients (9.4%) were diagnosed with COVID-19 and 877 died within 28 days. Individuals with stage 1 uncontrolled BP had lower odds of COVID-19 death (odds ratio, 0.76 [95% CI, 0.62–0.92]) compared with patients with well-controlled BP. There was no association between BP control and COVID-19 diagnosis or hospitalization. These findings suggest BP control may be associated with worse COVID-19 outcomes, possibly due to these patients having more advanced atherosclerosis and target organ damage. Such patients may need to consider adhering to stricter social distancing, to limit the impact of COVID-19 as future waves of the pandemic occur.